Wells Fargo analyst Tiago Fauth lowered the firm’s price target on Amicus (FOLD) to $17 from $18 and keeps an Overweight rating on the shares. The firm notes the company reported fairly in-line earnings, with no material updates vs pre-announcement. PomOp launch remains the focus of the stock and Amicus continues to execute well with Australia approval recently granted.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus’s Strategic Market Expansion and Strong Financial Outlook Drive Buy Rating
- Amicus Therapeutics Posts Robust 2024 Financial Growth
- Amicus Therapeutics: Promising Growth and Strong Financial Guidance Justify Buy Rating
- Amicus files automatic mixed securities shelf
- Amicus Stock: Fully Priced Amid Promising Growth and Hold Rating Recommendation